CTOs on the Move

Garden of Life, Inc.

www.gardenoflife.com

 
Garden of Life, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in West Palm Beach, FL. To find more information about Garden of Life, Inc., please visit www.gardenoflife.com
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.gardenoflife.com
  • 5500 Village Blvd Ste 202
    West Palm Beach, FL USA 33407-1961
  • Phone: 561.748.2477

Executives

Name Title Contact Details

Similar Companies

Interactive Health

Interactive Health, the country’s leading provider of health management solutions, creates innovative wellness programs designed to increase overall company health and actively engage employees to make lasting behavior changes. For every company’s perspective on health management, early stage or mature, Interactive Health has a highly flexible program to meet its needs. By offering health evaluations that detect risk proactively, Interactive Health has the capability to immediately intervene and engage at-risk participants with a personalized course of action. Using ActiveEngine(TM), a proprietary algorithmic-based clinical intelligence engine, a unique achievable goal is assigned to each participant based on individual results and health improvements are measured. Interactive Health has a 20+ year track record of creating the Healthiest Companies in America.

Oak Hill Hospital

Oak Hill Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Oak Hill Hospital is based in Brooksville, FL. You can find more information on Oak Hill Hospital at www.oakhillhospital.com

Paynesville Area Healthcare System

Paynesville Area Healthcare System is a Paynesville, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Citrus Health Care

Citrus Health Care is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scynexis

SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.